[A phase II study of cisplatin in gastric cancer. Kyushu Cisplatin Chemotherapy Group].
A multi-institutional cooperative phase II study of cisplatin for gastric cancer was conducted. Cisplatin was administered by i.v. infusion at 70-100 mg/m2 body surface area once every 3-4 weeks. Out of 28 cases entered, 25 were evaluable. No complete response was obtained and partial responses were observed in 3 cases, the overall response rate being 12.0%. Major adverse reactions were gastrointestinal symptoms, generalized malaise, bone marrow suppression and renal disorders.
D000230:Adenocarcinoma / Q000188:drug therapy; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy; D000328:Adult; D000368:Aged; D002291:Carcinoma, Papillary / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy*
D002945:Cisplatin